메뉴 건너뛰기




Volumn 102, Issue , 2015, Pages 63-70

Plasma uric acid concentrations are reduced by fenofibrate: A systematic review and meta-analysis of randomized placebo-controlled trials

Author keywords

Fenofibrate; Meta analysis; Uricaemia

Indexed keywords

BEZAFIBRATE; C REACTIVE PROTEIN; CHOLESTEROL; FENOFIBRATE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; URIC ACID;

EID: 84942872229     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2015.09.012     Document Type: Review
Times cited : (66)

References (34)
  • 1
    • 34248384541 scopus 로고    scopus 로고
    • Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers
    • M. Tomita, S. Mizuno, H. Yamanaka, and et al. Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers J. Epidemiol. 10 2000 403 409
    • (2000) J. Epidemiol. , vol.10 , pp. 403-409
    • Tomita, M.1    Mizuno, S.2    Yamanaka, H.3
  • 3
    • 0024508912 scopus 로고
    • Serum uric acid and 11.5-year mortality of middle-aged women: Findings of the Chicago Heart Association Detection Project in Industry
    • W. Levine, A.R. Dyer, R.B. Shekelle, J.A. Schoenberger, and J. Stamler Serum uric acid and 11.5-year mortality of middle-aged women: findings of the Chicago Heart Association Detection Project in Industry J. Clin. Epidemiol. 42 3 1989 257 267
    • (1989) J. Clin. Epidemiol. , vol.42 , Issue.3 , pp. 257-267
    • Levine, W.1    Dyer, A.R.2    Shekelle, R.B.3    Schoenberger, J.A.4    Stamler, J.5
  • 4
    • 73649149434 scopus 로고    scopus 로고
    • Uric acid in the acute phase of ST elevation myocardial infarction submitted to primary PCI: Its prognostic role and relation with inflammatory markers: A single center experience
    • C. Lazzeri, S. Valente, M. Chiostri, A. Sori, P. Bernardo, and G.F. Gensini Uric acid in the acute phase of ST elevation myocardial infarction submitted to primary PCI: its prognostic role and relation with inflammatory markers: a single center experience Int. J. Cardiol. 138 2 2010 206 209
    • (2010) Int. J. Cardiol. , vol.138 , Issue.2 , pp. 206-209
    • Lazzeri, C.1    Valente, S.2    Chiostri, M.3    Sori, A.4    Bernardo, P.5    Gensini, G.F.6
  • 5
    • 0027939881 scopus 로고
    • Impaired lipoprotein metabolism in patients with primary gout-influence of alcohol intake and body weight
    • S. Takahashi, T. Yamamoto, Y. Moriwaki, Z. Tsutsumi, and K. Higashino Impaired lipoprotein metabolism in patients with primary gout-influence of alcohol intake and body weight Br. J. Rheumatol. 33 1994 731 734
    • (1994) Br. J. Rheumatol. , vol.33 , pp. 731-734
    • Takahashi, S.1    Yamamoto, T.2    Moriwaki, Y.3    Tsutsumi, Z.4    Higashino, K.5
  • 6
    • 0035055141 scopus 로고    scopus 로고
    • Increased visceral fat accumulation further aggravates the risks of insulin resistance in gout
    • S. Takahashi, Y. Moriwaki, Z. Tsutsumi, J. Yamakita, T. Yamamoto, and T. Hada Increased visceral fat accumulation further aggravates the risks of insulin resistance in gout Metabolism 50 2001 393 398
    • (2001) Metabolism , vol.50 , pp. 393-398
    • Takahashi, S.1    Moriwaki, Y.2    Tsutsumi, Z.3    Yamakita, J.4    Yamamoto, T.5    Hada, T.6
  • 7
    • 0345314392 scopus 로고
    • The effect of a low purine diet and allopurinol on serum urate concentrations
    • B.T. Emmerson The effect of a low purine diet and allopurinol on serum urate concentrations Aust. Ann. Med. 16 1969 205 214
    • (1969) Aust. Ann. Med. , vol.16 , pp. 205-214
    • Emmerson, B.T.1
  • 8
    • 0037449776 scopus 로고    scopus 로고
    • An extremely potent inhibitor of xanthine oxidoreductase: Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition
    • K. Okamoto, B.T. Eger, T. Nishino, S. Kondo, E.F. Pai, and T. Nishino An extremely potent inhibitor of xanthine oxidoreductase: crystal structure of the enzyme-inhibitor complex and mechanism of inhibition J. Biol. Chem. 278 2003 1848 1855
    • (2003) J. Biol. Chem. , vol.278 , pp. 1848-1855
    • Okamoto, K.1    Eger, B.T.2    Nishino, T.3    Kondo, S.4    Pai, E.F.5    Nishino, T.6
  • 9
    • 10344260696 scopus 로고    scopus 로고
    • Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers
    • M.A. Becker, J. Kisicki, R. Khosravan, and et al. Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers Nucleosides Nucleotides Nucleic Acids 23 2004 1111 1116
    • (2004) Nucleosides Nucleotides Nucleic Acids , vol.23 , pp. 1111-1116
    • Becker, M.A.1    Kisicki, J.2    Khosravan, R.3
  • 10
    • 0019126936 scopus 로고
    • Uricosuric effect of fenofibrate in healthy volunteers
    • J.P. Desager, R. Hulhoven, and C. Harvengt Uricosuric effect of fenofibrate in healthy volunteers J. Clin. Pharmacol. 20 1980 560 564
    • (1980) J. Clin. Pharmacol. , vol.20 , pp. 560-564
    • Desager, J.P.1    Hulhoven, R.2    Harvengt, C.3
  • 11
    • 67650844186 scopus 로고    scopus 로고
    • Fenofibrate: Simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients
    • G. Derosa, P. Maffioli, S.A. Salvadeo, and et al. Fenofibrate: simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients Curr. Med. Res. Opin. 25 8 2009 1973 1983
    • (2009) Curr. Med. Res. Opin. , vol.25 , Issue.8 , pp. 1973-1983
    • Derosa, G.1    Maffioli, P.2    Salvadeo, S.A.3
  • 12
    • 0036894204 scopus 로고    scopus 로고
    • Comparison of gemfibrozil and fenofibrate in patients with dyslipidemic coronary heart disease
    • K.A. Packard, J.M. Backes, T.L. Lenz, R.L. Wurdeman, C. Destache, and D.E. Hilleman Comparison of gemfibrozil and fenofibrate in patients with dyslipidemic coronary heart disease Pharmacotherapy 22 12 2002 1527 1532
    • (2002) Pharmacotherapy , vol.22 , Issue.12 , pp. 1527-1532
    • Packard, K.A.1    Backes, J.M.2    Lenz, T.L.3    Wurdeman, R.L.4    Destache, C.5    Hilleman, D.E.6
  • 13
    • 69449100622 scopus 로고    scopus 로고
    • PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
    • D. Moher, A. Liberati, J. Tetzlaff, and D.G. Altman PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement BMJ 339 2009 b2535
    • (2009) BMJ , vol.339 , pp. b2535
    • Moher, D.1    Liberati, A.2    Tetzlaff, J.3    Altman, D.G.4
  • 17
    • 84876135427 scopus 로고    scopus 로고
    • Does PPARγ2 gene Pro12Ala polymorphism affect non alcoholic fatty liver disease risk? Evidence from a meta-analysis
    • A. Sahebkar Does PPARγ2 gene Pro12Ala polymorphism affect non alcoholic fatty liver disease risk? Evidence from a meta-analysis DNA Cell Biol. 32 4 2013 188 198
    • (2013) DNA Cell Biol. , vol.32 , Issue.4 , pp. 188-198
    • Sahebkar, A.1
  • 18
    • 84899477785 scopus 로고    scopus 로고
    • Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis
    • A. Sahebkar Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis Phytother. Res. 28 5 2014 633 642
    • (2014) Phytother. Res. , vol.28 , Issue.5 , pp. 633-642
    • Sahebkar, A.1
  • 19
    • 0033934949 scopus 로고    scopus 로고
    • Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis
    • S. Duval, and R. Tweedie Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis Biometrics 56 2000 455 463
    • (2000) Biometrics , vol.56 , pp. 455-463
    • Duval, S.1    Tweedie, R.2
  • 20
    • 0033384110 scopus 로고    scopus 로고
    • Atherogenic lipoprotein phenotype in type 2 diabetes: Reversal with micronised fenofibrate
    • M.D. Feher, M. Caslake, J. Foxton, A. Cox, and C.J. Packard Atherogenic lipoprotein phenotype in type 2 diabetes: reversal with micronised fenofibrate Diabetes Metab. Res. Rev. 15 6 1999 395 399
    • (1999) Diabetes Metab. Res. Rev. , vol.15 , Issue.6 , pp. 395-399
    • Feher, M.D.1    Caslake, M.2    Foxton, J.3    Cox, A.4    Packard, C.J.5
  • 21
    • 0036810635 scopus 로고    scopus 로고
    • Effects of fenofibrate on high-density lipoprotein particle size in patients with hyperlipidemia: A randomized, double-blind, placebo-controlled, multicenter, crossover study
    • J. Sasaki, K. Yamamoto, and M. Ageta Effects of fenofibrate on high-density lipoprotein particle size in patients with hyperlipidemia: a randomized, double-blind, placebo-controlled, multicenter, crossover study Clin. Ther. 24 10 2002 1614 1626
    • (2002) Clin. Ther. , vol.24 , Issue.10 , pp. 1614-1626
    • Sasaki, J.1    Yamamoto, K.2    Ageta, M.3
  • 22
    • 0036890093 scopus 로고    scopus 로고
    • Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus
    • D.A. Playford, G.F. Watts, J.D. Best, and V. Burke Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus Am. J. Cardiol. 90 11 2002 1254 1257
    • (2002) Am. J. Cardiol. , vol.90 , Issue.11 , pp. 1254-1257
    • Playford, D.A.1    Watts, G.F.2    Best, J.D.3    Burke, V.4
  • 23
    • 0141617491 scopus 로고    scopus 로고
    • Effects of fenofibrate on albuminuria in patients with hypertriglyceridemia and/or hyperuricemia: A multicenter, randomized, double-blind, placebo-controlled, crossover study
    • T. Kazumi, T. Hirano, G. Yoshino, and For The Fenofibrate Study Group Effects of fenofibrate on albuminuria in patients with hypertriglyceridemia and/or hyperuricemia: a multicenter, randomized, double-blind, placebo-controlled, crossover study Curr. Ther. Res. Clin. Exp. 64 7 2003 434 446
    • (2003) Curr. Ther. Res. Clin. Exp. , vol.64 , Issue.7 , pp. 434-446
    • Kazumi, T.1    Hirano, T.2    Yoshino, G.3
  • 24
    • 0023905821 scopus 로고
    • Hypertriglyceridemia and hyperuricemia: Effects of two fibric acid derivatives (bezafibrate and fenofibrate) in a double-blind, placebo-controlled trial
    • M.D. Bastow, P.N. Durrington, and M. Ishola Hypertriglyceridemia and hyperuricemia: effects of two fibric acid derivatives (bezafibrate and fenofibrate) in a double-blind, placebo-controlled trial Metabolism 37 3 1988 217 220
    • (1988) Metabolism , vol.37 , Issue.3 , pp. 217-220
    • Bastow, M.D.1    Durrington, P.N.2    Ishola, M.3
  • 25
    • 43849083545 scopus 로고    scopus 로고
    • Effect of fenofibrate on kidney function: A 6-week randomized crossover trial in healthy people
    • J.C. Ansquer, R.N. Dalton, E. Caussé, D. Crimet, K. Le Malicot, and C. Foucher Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people Am. J. Kidney Dis. 51 6 2008 904 913
    • (2008) Am. J. Kidney Dis. , vol.51 , Issue.6 , pp. 904-913
    • Ansquer, J.C.1    Dalton, R.N.2    Caussé, E.3    Crimet, D.4    Le Malicot, K.5    Foucher, C.6
  • 28
    • 75749156653 scopus 로고    scopus 로고
    • Effect of fenofibrate on uric acid metabolism and urate transporter 1
    • D. Uetake, I. Ohno, K. Ichida, and et al. Effect of fenofibrate on uric acid metabolism and urate transporter 1 Intern. Med. 49 2 2010 89 94
    • (2010) Intern. Med. , vol.49 , Issue.2 , pp. 89-94
    • Uetake, D.1    Ohno, I.2    Ichida, K.3
  • 29
    • 0037161834 scopus 로고    scopus 로고
    • Molecular identification of a renal urate anion exchanger that regulates blood urate levels
    • A. Enomoto, H. Kimura, A. Chairoungdua, and et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels Nature 417 6887 2002 447 452
    • (2002) Nature , vol.417 , Issue.6887 , pp. 447-452
    • Enomoto, A.1    Kimura, H.2    Chairoungdua, A.3
  • 30
    • 84906653638 scopus 로고    scopus 로고
    • Recent advances in pharmacotherapy for hypertriglyceridemia
    • A. Sahebkar, G.T. Chew, and G.F. Watts Recent advances in pharmacotherapy for hypertriglyceridemia Prog. Lipid Res. 56 2014 47 66
    • (2014) Prog. Lipid Res. , vol.56 , pp. 47-66
    • Sahebkar, A.1    Chew, G.T.2    Watts, G.F.3
  • 31
    • 84882927131 scopus 로고    scopus 로고
    • New LDL-cholesterol lowering therapies: Pharmacology, clinical trials, and relevance to acute coronary syndromes
    • A. Sahebkar, and G.F. Watts New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes Clin. Ther. 35 8 2013 1082 1098
    • (2013) Clin. Ther. , vol.35 , Issue.8 , pp. 1082-1098
    • Sahebkar, A.1    Watts, G.F.2
  • 32
    • 84892369781 scopus 로고    scopus 로고
    • New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: What can the clinician expect?
    • A. Sahebkar, and G.F. Watts New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect? Cardiovasc Drugs Ther. 27 6 2013 559 567
    • (2013) Cardiovasc Drugs Ther. , vol.27 , Issue.6 , pp. 559-567
    • Sahebkar, A.1    Watts, G.F.2
  • 33
    • 84905746950 scopus 로고    scopus 로고
    • Role of selective peroxisome proliferator-activated receptor modulators in managing cardiometabolic disease: Tale of a roller-coaster
    • A. Sahebkar, and G.F. Watts Role of selective peroxisome proliferator-activated receptor modulators in managing cardiometabolic disease: tale of a roller-coaster Diabetes Obes. Metab. 16 9 2014 780 792
    • (2014) Diabetes Obes. Metab. , vol.16 , Issue.9 , pp. 780-792
    • Sahebkar, A.1    Watts, G.F.2
  • 34
    • 84893649359 scopus 로고    scopus 로고
    • New peroxisome proliferator-activated receptor agonists: Potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease
    • A. Sahebkar, G.T. Chew, and G.F. Watts New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease Expert Opin. Pharmacother. 15 4 2014 493 503
    • (2014) Expert Opin. Pharmacother. , vol.15 , Issue.4 , pp. 493-503
    • Sahebkar, A.1    Chew, G.T.2    Watts, G.F.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.